GlassScriptPhysician profile
Robert N Jenkins
NPI 1518966100
$66,340.89
in general payments reported to CMS, 2019-2025
39 companies · $2,217 in 2025
The $2,217 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $5,370 · 2021: $8,828 · 2022: $17K · 2023: $10K · 2024: $5,090 · 2025: $2,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $6,814 · Education: $38.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,775.00 |
| Food and Beverage | $6,814.24 |
| Education | $38.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $56,818.39 | 2019-2025 | |
| Amgen INC. | $2,188.13 | 2019-2025 | Enbrel, Evenity, Otezla |
| Pfizer INC. | $1,564.52 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,075.79 | 2019-2025 | |
| Emd Serono, INC. | $716.69 | 2019 | |
| Ucb, INC. | $712.46 | 2019-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $568.57 | 2019-2025 | Saphnelo |
| Horizon Therapeutics Plc | $445.76 | 2019-2023 | Krystexxa |
| Edwards Lifesciences Corporation | $408.39 | 2019-2021 | |
| Genentech USA, INC. | $342.89 | 2019-2025 | Actemra, Gazyva |
| Glaxosmithkline, LLC. | $303.04 | 2019-2023 | Benlysta |
| Lilly USA, LLC | $170.19 | 2019-2025 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $149.24 | 2019-2025 | Orencia |
| Fresenius Kabi USA, LLC | $108.29 | 2025 | Idacio |
| Celgene Corporation | $91.86 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $59.46 | 2019 | |
| Alexion Pharmaceuticals, INC. | $47.93 | 2025 | Strensiq |
| Alnylam Pharmaceuticals INC. | $47.24 | 2022 | |
| Scilex Pharmaceuticals INC. | $46.47 | 2024 | |
| Pacira Therapeutics, INC. | $42.18 | 2020 | |
| Genzyme Corporation | $41.88 | 2020 | |
| Kyowa Kirin, INC. | $38.02 | 2024 | Crysvita |
| Medtronic, INC. | $37.42 | 2023 | Corevalve Evolut R |
| Aurinia Pharma U.S., INC. | $36.71 | 2023-2024 | Lupkynis |
| Invivyd INC | $29.74 | 2025 | Pemgarda |
| Radius Health, INC. | $28.40 | 2019-2020 | |
| Abbott Laboratories | $23.34 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.07 | 2025 | |
| Sanofi-Aventis U.S. LLC | $21.63 | 2019 | |
| Sandoz INC. | $20.07 | 2025 | Jubbonti |
| Sobi, INC | $19.25 | 2024 | |
| Celltrion USA INC. | $19.05 | 2023 | Yuflyma |
| Tonix Medicines, INC. | $18.96 | 2025 | Tonmya |
| Kiniksa Pharmaceuticals, LTD. | $17.86 | 2023 | Arcalyst |
| Organon LLC | $16.82 | 2025 | Renflexis, Hadlima |
| Mallinckrodt Hospital Products INC. | $15.54 | 2024 | Acthar |
| Siemens Medical Solutions USA, INC. | $14.55 | 2019 | |
| Merck Sharp & Dohme LLC | $12.09 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Jenkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.